NCT01730209View on ClinicalTrials.gov

Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions
Tuberous Sclerosis ComplexTSC Related Cognitive DisabilityTSC Related AutismTSC Related Learning Problems
Interventions
DRUG

Everolimus

Everolimus once daily titrated to trough levels of 5-10 ng/ml.

DRUG

Placebo

Trial Locations (1)

Unknown

RECRUITING

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Utrecht University

OTHER

lead

Erasmus Medical Center

OTHER